Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $10.3000 (-3.33%) ($10.3000 - $10.3000) on Thu. Oct. 19, 2023. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.89% (three month average) | RSI | 27 | Latest Price | $10.3000(-3.33%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD advances 0.4% a day on average for past five trading days. | Weekly Trend | FOLD declines -3.1% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) XBI(73%) IBB(70%) ARKG(63%) IWO(58%) IWM(56%) | Factors Impacting FOLD price | FOLD will decline at least -1.445% in a week (0% probabilities). TBT(-44%) UUP(-21%) VXX(-19%) VIXM(-7%) USO(-2%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.445% (StdDev 2.89%) | Hourly BBV | -1.5 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-2.08(-120.19%) | Resistance Level | $11.14 | 5 Day Moving Average | $10.54(-2.28%) | 10 Day Moving Average | $10.64(-3.2%) | 20 Day Moving Average | $11.14(-7.54%) | To recent high | -25.3% | To recent low | 1.8% | Market Cap | $2.66b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |